# US 2017/0283408 A1 · Benzo-heterocyclic compounds and their applications

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0283408 A1
- Document ID: US20170283408A1
- Status: Published application
- Kind: A1
- Application number: 15/512,248
- Filed: 2015-09-17
- Published: 2017-10-05
- Earliest claimed: 2014-09-19
- Assignees: Yen-Ta Lu
- Inventors: YEN-TA LU; TZENGE-LIEN SHIH; CHIA-MING CHANG; TSAI-YIN WEI; JEN-WEI LIU
- Web page: https://patentgrep.com/patent/US20170283408A1

## CPC

- C07D 417/04: directly linked by a ring-member-to-ring-member bond
- A61K 31/4035: Isoindoles, e.g. phthalimide
- A61K 31/473: ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A61K 31/635: having a heterocyclic ring, e.g. sulfadiazine
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/04: Antibacterial agents
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 209/48: with oxygen atoms in positions 1 and 3, e.g. phthalimide
- C07D 221/06: Ring systems of three rings
- C07D 221/14: Aza-phenalenes, e.g. 1,8-naphthalimide
- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- C07K 16/2818: {against CD28 or CD152}
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to benzoxazole derivatives having the following Formula (I): The compounds of the present invention are found to possess the ability to decrease PD-L1 level, suggesting that the compounds of the invention can be used in cancer immunotherapy and treatment or prevention of sepsis or septic shock.

## Claims

### Claim 1

A compound having the following Formula (I),
wherein
n is 0 or 1;
R1 is selected from halogen, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, haloC1-10alkyl, hydroxyC1-10alkyl, aminoC1-10alkyl, C3-10cycloalkyl, 3 to 10 membered cyclic heterocycloalkyl having 1 to 3 heteroatoms selected from N, S and O, C6-10aryl or 5 to 10 membered mono- or bi-cyclic heteroaryl having from 1 to 3 heteroatoms selected from N, S and O, wherein the amino moiety of aminoalkyl is unsubstituted or substituted by one or two alkyl groups, and the cycloalkyl, heterocycloalkyl, aryl and heteroaryl are substituted by —SO2NH2, or —CONH2;
R2 is selected from hydrogen, halogen, hydroxy, amino, cyano, nitro, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, C1-10alkoxy, C1-10alkylthio, C1-10alkylamino, haloC1-10alkyl, hydroxyC1-10alkyl, aminoC1-10alkyl, C3-10cycloalkyl, 3 to 10 membered cyclic heterocycloalkyl having 1 to 3 heteroatoms selected from N, S and O, C6-10aryl or 5 to 10 membered mono- or bi-cyclic heteroaryl having from 1 to 3 heteroatoms selected from N, S and O;
R3 is selected from hydrogen, halogen, hydroxy, amino, cyano, nitro, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, C1-10alkoxy, C1-10alkylthio, C1-10alkylamino, haloC1-10alkyl, hydroxyC1-10alkyl, aminoC1-10alkyl, C3-10cycloalkyl, 3 to 10 membered cyclic heterocycloalkyl having 1 to 3 heteroatoms selected from N, S and O, C6-10aryl or 5 to 10 membered mono- or bi-cyclic heteroaryl having from 1 to 3 heteroatoms selected from N, S and O; or
R2 and R3 together with carbon atoms to which they attach form a benzene ring, wherein the benzene ring is unsubstituted or substituted by one or more groups independently selected from halogen, hydroxy, amino, cyano, nitro, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, C1-10alkoxy, C1-10alkylthio, C1-10alkylamino, haloC1-10alkyl, hydroxyC1-10alkyl, aminoC1-10alkyl, C3-10cycloalkyl, 3 to 10 membered cyclic heterocycloalkyl having 1 to 3 heteroatoms selected from N, S and O, C6-10aryl or 5 to 10 membered mono- or bi-cyclic heteroaryl having from 1 to 3 heteroatoms selected from N, S and O, with the proviso that n is 1; and
R4, R5 and R6 are each independently selected from hydrogen, halogen, hydroxy, amino, cyano, nitro, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, C1-10alkoxy, C1-10alkylthio, C1-10alkylamino, haloC1-10alkyl, hydroxyC1-10alkyl, aminoC1-10alkyl, C3-10cycloalkyl, 3 to 10 membered cyclic heterocycloalkyl having 1 to 3 heteroatoms selected from N, S and O, C6-10aryl or 5 to 10 membered mono- or bi-cyclic heteroaryl having from 1 to 3 heteroatoms selected from N, S and O;
wherein the cycloalkyl, heterocycloalkyl, aryl and heteroaryl in R2 to R6 may be unsubstituted or substituted by one to four groups selected from halogen, amino, cyano, nitro, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, C1-10alkoxy, C1-10alkylthio, C1-10alkylamino, haloC1-10alkyl, hydroxyC1-10alkyl, aminoC1-10alkyl, C3-10cycloalkyl;
with provisos that (1) when n is 1, R1 is
and R2 and R3 together with carbon atoms to which they attach form a benzene ring, R4, R5 and R6 cannot simultaneously represent hydrogen; (2) when n is 0 and R1 is selected from the cycloalkyl, heterocycloalkyl, aryl or heteroaryl, R3, R4, R5 and R6 are not simultaneously hydrogen; (3) when n is 0, R1 is
and R3 and R6 simultaneously represent hydrogen, if one of R4 and R5 is hydrogen, the other cannot be methyl, tert-butyl or nitro; (4) when n is 0, R1 is
and R3 and R6 simultaneously represent hydrogen, R4 and R5 cannot simultaneously represent chloro; and (5) when n is 0 and R1 is
R3, R4, R5 and R6 cannot simultaneously represent chloro;
or a tautomer, stereoisomer or enantiomer thereof, or a solvate, prodrug or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound of claim 1, wherein n is 1; R1 is (C1-10(di)alkylamino)C1-10alkyl, hydroxyC1-10alkyl or C6-10aryl substituted by —SO2NH2 or —CO2NH2; R2 and R3 together with carbon atoms to which they attach form a benzene ring, wherein the benzene ring is unsubstituted or substituted by one or more groups independently selected from halogen, amino, cyano, nitro or C1-10alkyl; R4 is H, halogen or 5 to 10 membered mono- or bi-cyclic, unsubstituted or substituted heteroaryl having from 1 to 3 heteroatoms selected from N, S and O; and R5 and R6 are each independently hydrogen, halogen, amino, cyano, nitro, C1-10alkyl or haloC1-10alkyl; or a tautomer, stereoisomer or enantiomer thereof, or a solvate, prodrug or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1)

The compound of claim 1, wherein n is 1, R1 is (C1-6(di)alkylamino)C1-6alkyl, hydroxyC1-6alkyl or phenyl substituted by —SO2NH2; R2 and R3 together with carbon atoms to which they attach form an unsubstituted benzene ring; R4 is H, halogen or 9 to 10 membered bi-cyclic, unsubstituted or substituted heteroaryl having from two heteroatoms selected from N, S and O; and R5 and R6 are each independently hydrogen, halogen, nitro or C1-6alkyl; or a tautomer, stereoisomer or enantiomer thereof, or a solvate, prodrug or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1)

The compound of claim 1, wherein n is 1, R1 is —CH2CH2N(CH3)2, —CH2CH2OH, —(CH2)3CH3 or phenyl substituted by —SO2NH2, R2 and R3 together with carbon atoms to which they attach form an unsubstituted benzene ring; R4 is
and R5 and R6 are each independently hydrogen, halogen, nitro or C1-4alkyl; or a tautomer, stereoisomer or enantiomer thereof, or a solvate, prodrug or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 1)

The compound of claim 1, wherein n is 0, R1 is C6-10aryl substituted by —SO2NH2 or —CO2NH2; and R3, R4, R5 and R6 are each independently selected from hydrogen, halogen, amino, cyano, nitro or C1-10alkyl; or a tautomer, stereoisomer or enantiomer thereof, or a solvate, prodrug or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 1)

The compound of claim 1, wherein n is 0, R1 is phenyl substituted by —SO2NH2; R3 and R6 are each independently selected from hydrogen, halogen or C1-6alkyl; and R4 and R5 are each independently selected from hydrogen, halogen, nitro or C1-6alkyl; or a tautomer, stereoisomer or enantiomer thereof, or a solvate, prodrug or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 1)

The compound of claim 1, wherein n is 0, R1 is phenyl substituted by —SO2NH2; R3 and R6 are each independently selected from hydrogen, halogen or C1-4alkyl; and R4 and R5 are each independently selected from hydrogen, halogen, nitro or C1-4alkyl; or a tautomer, stereoisomer or enantiomer thereof, or a solvate, prodrug or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 1)

The compound of claim 1, wherein n is 0, R1 is phenyl substituted by —SO2NH2; R3 and R6 are each independently selected from hydrogen or halogen; and R4 and R5 are each independently selected from hydrogen, halogen, nitro or C1-4alkyl; or a tautomer, stereoisomer or enantiomer thereof, or a solvate, prodrug or a pharmaceutically acceptable salt thereof.

### Claim 9 (depends on 1)

The compound of claim 1, which is selected from the group consisting of the following:
Compound
Name
n
R1
R2
R3
R4
R5
R6
ML-A1-B
1
—CH2CH2N(CH3)2
═CH—CH═CH—
H
H
ML-A1-C
1
—CH2CH2N(CH3)2
═CH—CH═CH—
H
H
ML-A1-K
1
—CH2CH2OH
═CH—CH═CH—
H
H
ML-A1-L
1
—CH2CH2OH
═CH—CH═CH—
H
H
ML-A1-I
1
—(CH2)3CH3
═CH—CH═CH—
H
H
ML-C19-B
1
═CH—CH═CH—
Br
H
H
ML-C19-PH2
0
—
H
H
Br
H
ML-C19-PH3
0
—
Br
Br
Br
Br
ML-C19-PH4
0
—
H
H
CH3
H
ML-C19-PH6
0
—
H
H
H
NO2
or a tautomer, stereoisomer or enantiomer thereof, or a solvate, prodrug or a pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 1)

The compound of claim 1, which is 4-(6-bromo-1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)benzene-sulfonamide (compound ML-C19-B) and has the following formula:
or a tautomer, stereoisomer or enantiomer thereof, or a solvate, prodrug or a pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 1)

The compound of claim 1, which has the following formula:
wherein X is O or S or N; or a tautomer, stereoisomer or enantiomer thereof, or a solvate, prodrug or a pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 1)

The compound of claim 1, which is
or a tautomer, stereoisomer or enantiomer thereof, or a solvate, prodrug or a pharmaceutically acceptable salt thereof.

### Claim 13 (depends on 1)

A pharmaceutical composition comprising an effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 14 (depends on 13)

The pharmaceutical composition of claim 13, further comprising a second active agent.

### Claim 15 (depends on 14)

The pharmaceutical composition of claim 14, wherein the second active agent is an anticancer agent or an immune checkpoint inhibitor.

### Claim 16 (depends on 15)

The pharmaceutical composition of claim 15, wherein the immune checkpoint inhibitor is an anti-PD-L1 antibody, an anti-PD-1 antibody or an anti-CTLA-4 antibody.

### Claim 17 (depends on 15)

The pharmaceutical composition of claim 15, wherein the immune checkpoint inhibitor is ipilimumab, lambrolizumab, MPDL3280A, MEDI4736 or avelumab.

### Claim 18 (depends on 15)

The pharmaceutical composition of claim 15, wherein the second anticancer agent is an antimetabolite, antimicrotubule agent, alkylating agent, platinum agent, anthracycline, antitumor antibiotic, topoisomerase inhibitor, purine antagonist or pyrimidine antagonist, cell maturing agent, DNA repair enzyme inhibitor, histone deacetylase inhibitor, cytotoxic agent, hormone, anti-cancer monoclonal antibody, immuno-modulator, Bcr-Abl kinase inhibitor or hormone agonist or antagonist.

### Claim 19 (depends on 13)

A method for inhibiting PD-L1 level in a subject, comprising administering an effective amount of a compound as defined below or a pharmaceutical composition of claim 13 to the subject;
wherein
n is 0 or 1,
R1 is selected from halogen, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, haloC1-10alkyl, hydroxyC1-10alkyl, aminoC1-10alkyl, C3-10cycloalkyl, 3 to 10 membered cyclic heterocycloalkyl having 1 to 3 heteroatoms selected from N, S and O, C6-10aryl or 5 to 10 membered mono- or bi-cyclic heteroaryl having from 1 to 3 heteroatoms selected from N, S and O, wherein the amino moiety of aminoalkyl is unsubstituted or substituted by one or two alkyl groups, and the cycloalkyl, heterocycloalkyl, aryl and heteroaryl are substituted by —SO2NH2, or —CONH2;
R2 is selected from hydrogen, halogen, hydroxy, amino, cyano, nitro, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, C1-10alkoxy, C1-10alkylthio, C1-10alkylamino, haloC1-10alkyl, hydroxyC1-10alkyl, aminoC1-10alkyl, C3-10cycloalkyl, 3 to 10 membered cyclic heterocycloalkyl having 1 to 3 heteroatoms selected from N, S and O, C6-10aryl or 5 to 10 membered mono- or bi-cyclic heteroaryl having from 1 to 3 heteroatoms selected from N, S and O;
R3 is selected from hydrogen, halogen, hydroxy, amino, cyano, nitro, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, C1-10alkoxy, C1-10alkylthio, C1-10alkylamino, haloC1-10alkyl, hydroxyC1-10alkyl, aminoC1-10alkyl, C3-10cycloalkyl, 3 to 10 membered cyclic heterocycloalkyl having 1 to 3 heteroatoms selected from N, S and O, C6-10aryl or 5 to 10 membered mono- or bi-cyclic heteroaryl having from 1 to 3 heteroatoms selected from N, S and O; or
R2 and R3 together with carbon atoms to which they attach form a benzene ring, wherein the benzene ring is unsubstituted or substituted by one or more groups independently selected from halogen, hydroxy, amino, cyano, nitro, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, C1-10alkoxy, C1-10alkylthio, C1-10alkylamino, haloC1-10alkyl, hydroxyC1-10alkyl, aminoC1-10alkyl, C3-10cycloalkyl, 3 to 10 membered cyclic heterocycloalkyl having 1 to 3 heteroatoms selected from N, S and O, C6-10aryl or 5 to 10 membered mono- or bi-cyclic heteroaryl having from 1 to 3 heteroatoms selected from N, S and O, with the proviso that n is 1; and
R4, R5 and R6 are each independently selected from hydrogen, halogen, hydroxy, amino, cyano, nitro, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, C1-10alkoxy, C1-10alkylthio, C1-10alkylamino, haloC1-10alkyl, hydroxyC1-10alkyl, aminoC1-10alkyl, C3-10cycloalkyl, 3 to 10 membered cyclic heterocycloalkyl having 1 to 3 heteroatoms selected from N, S and O, C6-10aryl or 5 to 10 membered mono- or bi-cyclic heteroaryl having from 1 to 3 heteroatoms selected from N, S and O;
wherein the cycloalkyl, heterocycloalkyl, aryl and heteroaryl in R2 to R6 may be unsubstituted or substituted by one to four groups selected from halogen, amino, cyano, nitro, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, C1-10alkoxy, C1-10alkylthio, C1-10alkylamino, haloC1-10alkyl, hydroxyC1-10alkyl, aminoC1-10alkyl, C3-10cycloalkyl;
or a tautomer, stereoisomer or enantiomer thereof, or a solvate, prodrug or a pharmaceutically acceptable salt thereof.

### Claim 20 (depends on 19)

The method of claim 19, wherein the compound is shown below:
Compound
Name
n
R1
R2
R3
R4
R5
R6
ML-A1-B
1
—CH2CH2N(CH3)2
═CH—CH═CH—
H
H
ML-A1-C
1
—CH2CH2N(CH3)2
═CH—CH═CH—
H
H
ML-A1-K
1
—CH2CH2OH
═CH—CH═CH—
H
H
ML-A1-L
1
—CH2CH2OH
═CH—CH═CH—
H
H
ML-A1-I
1
—(CH2)3CH3
═CH—CH═CH—
H
H
ML-C19-A
1
═CH—CH═CH—
H
H
H
ML-C19-B
1
═CH—CH═CH—
Br
H
H
ML-C19-PH2
0
—
H
H
Br
H
ML-C19-PH3
0
—
Br
Br
Br
Br
ML-C19-PH4
0
—
H
H
CH3
H
ML-C19-PH5
0
—
H
H
NO2
H
ML-C19-PH6
0
—
H
H
H
NO2

### Claim 21 (depends on 19)

The method of claim 19, wherein the compound is

### Claim 22 (depends on 19)

The method of claim 19, wherein the administration increases HLA-DR level.

### Claim 23 (depends on 19)

A method for treatment or prevention of a PD-L1-associated cancer or sepsis or septic shock in a subject, comprising administering an effective amount of a compound as defined in claim 19 or a pharmaceutical composition of the invention to a subject.

### Claim 24 (depends on 23)

The method of claim 23, wherein the PD-L1-associated cancer is renal cell carcinoma, ovarian cancer, lung cancer, NSCLC, colon cancer, hepatocellular carcinoma or melanoma.

### Claim 25 (depends on 23)

The method of claim 23, which comprises an additional step of sequentially, simultaneously, separately or subsequently administering an immune checkpoint inhibitor.

### Claim 26 (depends on 25)

The method of claim 25, wherein the immune checkpoint inhibitor is an anti-PD-L1 antibody, an anti-PD-1 antibody or an anti-CTLA-4 antibody.

### Claim 27 (depends on 25)

The method of claim 25, wherein the immune checkpoint inhibitor is ipilimumab, lambrolizumab, MPDL3280A, MEDI4736 or avelumab.

### Claim 28 (depends on 24)

The method of claim 24, which comprises an additional step of sequentially, simultaneously, separately or subsequently administering an immune checkpoint inhibitor.

### Claim 29 (depends on 28)

The method of claim 28, wherein the immune checkpoint inhibitor is an anti-PD-L1 antibody, an anti-PD-1 antibody or an anti-CTLA-4 antibody.

### Claim 30 (depends on 28)

The method of claim 28, wherein the immune checkpoint inhibitor is ipilimumab, lambrolizumab, MPDL3280A, MEDI4736 or avelumab.
